|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The likely primary importance of MYC to SCLC subtype transformation and recent attempts to drug MYC are discussed.
|
31445197 |
2019 |
|
Small cell carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
MYCN, a member of the MYC family, is correlated with tumorigenesis, metastasis and therapy in many malignancies; however, its role in small-cell lung cancer (SCLC) remains unclear.
|
31598396 |
2019 |
|
Small cell carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These analyses uncover MYC-paralog-specific regulation of the apoptotic machinery with implications for genotype-based selection of targeted therapeutics in SCLC patients.
|
31375684 |
2019 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
We performed steady state metabolomics on tumors isolated from distinct genetically engineered mouse models (GEMM) representing the MYC- and MYCL-driven subtypes of SCLC.
|
31164374 |
2019 |
|
Small cell carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These enzymes are transcriptional targets of MYC, which is selectively overexpressed in ASCL1<sup>Low</sup> SCLC.
|
30043754 |
2018 |
|
Small cell carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Targeted drug screening reveals that SCLC with high MYC expression is vulnerable to Aurora kinase inhibition, which, combined with chemotherapy, strongly suppresses tumor progression and increases survival.
|
28089889 |
2017 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, we will compare the distinct molecular features of the 3 MYC family members and address the potential implications for targeted therapy of SCLC.
|
28737478 |
2017 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Proteomic analysis identified CHK1 and MYC as top predictive biomarkers of LY2606368 sensitivity, suggesting that CHK1 inhibition may be especially effective in SCLC with <i>MYC</i> amplification or MYC protein overexpression.
|
28490518 |
2017 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The lung cancer subtypes share some genetic variations such as the dysfunction of tumor suppressor gene TP53, and also harbor specific variations of their own such as MET in ADC, FGFR1 and FGFR3 in SCC and MYC in SCLC.
|
27845189 |
2017 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting the glutaminolysis pathway might hence be a novel approach to selectively kill MYC amplified SCLC cells in vivo.
|
28430666 |
2017 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate pTIJ as a tool for the inducible expression of genes of interest, we introduced MYC cDNA into pTIJ and infected two small cell lung cancer cell lines, H209 and H345.
|
28447263 |
2017 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on a recent study that identified the spliceosome as a therapeutic vulnerability in MYC-driven breast cancers, we evaluated the efficacy of a spliceosome inhibitor in SCLC cell lines and analyzed the correlation with MYC status.
|
28192473 |
2017 |
|
Small cell carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Genetic and pharmacological inhibition of MYC in SCLC cells to non-TPC levels inhibits long-term propagation but not short-term growth.
|
27373157 |
2016 |
|
Small cell carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We next extended the platform to a second compound that had activity in SCLC cell lines lacking c-MYC amplification and identified TANK-binding kinase 1, a kinase that affects cell viability, polo-like kinase-1 signaling, G2-M arrest, and apoptosis in SCLC cells lacking MYC amplification.
|
26772203 |
2016 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results strongly indicate that SCLC cells carrying amplification of MYC, MYCL or MYCN are addicted to MYC function, suggesting that MYC targeting would be an efficient therapeutic option for SCLC patients.
|
27105536 |
2016 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The importance of ASCL1 as a potential driver oncogene in SCLC is further underscored by the observation that ASCL1 is overexpressed in >50% of SCLC specimens, an extent greater than that observed for other putative oncogenes (MYC, MYCN, and SOX2) previously implicated in SCLC.
|
26253517 |
2015 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Control of the MYC-eIF4E axis may be a novel therapeutic strategy for everolimus action in SCLC.
|
25884680 |
2015 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Emerging target treatments associated with MYC status in SCLC necessitates the evaluation of MYC using current methodologies, such as CISH.
|
25012251 |
2014 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this issue of Cancer Discovery, Romero and colleagues identify somatic mutations and deletions of MAX, and also define what seem to be mutually exclusive alterations in MYC family members and other MYC-associated factors in small cell lung cancer.
|
24596200 |
2014 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Predictive value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPΟ-IIA, TOPOIIB and C-MYC genes in patients with small cell lung cancer (SCLC) who received first line therapy with cisplatin and etoposide.
|
24058603 |
2013 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, the 9p24.1 region was identified as being amplified in SCLCs without amplification of MYC family oncogenes.
|
23716474 |
2013 |
|
Small cell carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In vivo experiments with two SCLC xenograft models confirmed the sensitivity of Myc gene-driven models to PF-03814735 and a possible schedule dependence of MYC/c-Myc-driven tumors.
|
22222631 |
2012 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In MYC-amplified SCLC cells Aurora kinase inhibition associates with G2/M-arrest, inactivation of PI3-kinase (PI3K) signaling, and induction of apoptosis.
|
23035247 |
2012 |
|
Small cell carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In contrast, CN alterations of the TP53 gene and the MYC family members were predominantly observed in SCLC.
|
20615970 |
2010 |
|
Small cell carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification.
|
16116477 |
2006 |